Coordinated regulation of myeloid cells by tumours

Nature Reviews Immunology

Volumn 12, Issue 4, 2012, Pages 253-268

  Gabrilovich, Dmitry I ^a   Ostrand Rosenberg, Suzanne ^b   Bronte, Vincenzo ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; AFLIBERCEPT; BEVACIZUMAB; CCAAT ENHANCER BINDING PROTEIN BETA; CELECOXIB; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; DOCETAXEL; FURAZOLIDONE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GW 2580; MACROPHAGE DERIVED CHEMOKINE; MONOCLONAL ANTIBODY; PLERIXAFOR; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE C BETA; PROTEIN TYROSINE KINASE INHIBITOR; PROTEOLIPOSOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SILDENAFIL; STAT3 PROTEIN; STEM CELL FACTOR; SUNITINIB; TADALAFIL; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADAPTIVE IMMUNITY; ANGIOGENESIS; BONE MARROW CELL; BREAST CANCER; BREAST CARCINOMA; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SUBPOPULATION; COLON CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME INDUCTION; FIBROSARCOMA; GLIOMA; GRANULOCYTE; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG CANCER; LUNG CARCINOMA; LYMPHOMA; MACROPHAGE; MESOTHELIOMA; MIXED LYMPHOCYTE REACTION; NONHUMAN; OXIDATIVE STRESS; POLARIZATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; SARCOMA; TH1 CELL; TH2 CELL; THYMOMA; TREATMENT FAILURE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNE TOLERANCE; MYELOID CELLS; NEOPLASMS;

EID: 84858785703     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3175     Document Type: Review

References (215)

1. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51 (2010).
2. Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol. 11, 889-896 (2010).
3. Coussens, L. M. & Pollard, J. W. Leukocytes in mammary development and cancer. Cold Spring Harb. Perspect. Biol. 3, a003285 (2011).
4. Khazaie, K. et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 30, 45-60 (2011).
5. Liu, K. & Nussenzweig, M. C. Origin and development of dendritic cells. Immunol. Rev. 234, 45-54 (2010).
6. Fogg, D. K. et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311, 83-87 (2006). (Pubitemid 43063063)
7. Onai, N. et al. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nature Immunol. 8, 1207-1216 (2007). (Pubitemid 350011759)
8. Naik, S. H. et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nature Immunol. 8, 1217-1226 (2007). (Pubitemid 350011760)
9. Shortman, K. & Heath, W. R. The CD8+ dendritic cell subset. Immunol. Rev. 234, 18-31 (2010).
10. Idoyaga, J. & Steinman, R. M. SnapShot: dendritic cells. Cell 146, 660-660.e2 (2011).
11. Swiecki, M. & Colonna, M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 234, 142-162 (2010).
12. Dominguez, P. M. & Ardavin, C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 234, 90-104 (2010).
13. Gabrilovich, D. I. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev. Immunol. 4, 941-952 (2004).
14. Pinzon-Charry, A. et al. Numerical and functional defects of blood dendritic cells in early-and late-stage breast cancer. Br. J. Cancer 97, 1251-1259 (2007). (Pubitemid 350035809)
15. Perrot, I. et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol. 178, 2763-2769 (2007). (Pubitemid 46333153)
16. Bellone, G. et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J. Immunol. 177, 3448-3460 (2006). (Pubitemid 44277866)
17. Lee, B. N. et al. Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions. Cancer 107, 999-1007 (2006).
18. Ormandy, L. A. et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J. Gastroenterol. 12, 3275-3282 (2006). (Pubitemid 43881355)
19. Pinzon-Charry, A., Maxwell, T. & Lopez, J. A. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell Biol. 83, 451-461 (2005). (Pubitemid 41805745)
20. Mancino, A. et al. Divergent effects of hypoxia on dendritic cell functions. Blood 112, 3723-3734 (2008).
21. Elia, A. R. et al. Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. J. Leukoc. Biol. 84, 1472-1482 (2008). (Pubitemid 352774482)
22. Yang, M. et al. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol. Cell Biol. 88, 165-171 (2010).
23. Novitskiy, S. V. et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112, 1822-1831 (2008).
24. Gottfried, E. et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013-2021 (2006). (Pubitemid 43289385)
25. Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nature Med. 16, 880-886 (2010).
26. Ghiringhelli, F. et al. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202, 919-929 (2005). (Pubitemid 41396892)
27. Lin, A., Schildknecht, A., Nguyen, L. T. & Ohashi, P. S. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol. Lett. 127, 77-84 (2010).
28. Norian, L. A. et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via l-arginine metabolism. Cancer Res. 69, 3086-3094 (2009).
29. Watkins, S. K. et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121, 1361-1372 (2011).
30. Dumitriu, I. E., Dunbar, D. R., Howie, S. E., Sethi, T. & Gregory, C. D. Human dendritic cells produce TGF-β1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 182, 2795-2807 (2009).
31. Liu, Q. et al. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J. Immunol. 182, 6207-6216 (2009).
32. Lee, J. R. et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 83, 1457-1466 (2003). (Pubitemid 37267829)
33. Munn, D. H. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290 (2004). (Pubitemid 39071633)
34. Baban, B. et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183, 2475-2483 (2009).
35. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nature Rev. Immunol. 8, 958-969 (2008).
36. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (2002). (Pubitemid 35223554)
37. Mantovani, A., Sica, A., Allavena, P., Garlanda, C. & Locati, M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 70, 325-330 (2009).
38. Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237 (2010).
39. Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362, 875-885 (2010).
40. This study identified a gene signature of TAMs that was associated with primary treatment failure in patients with Hodgkin's lymphoma, and demonstrated that the number of macrophages in patients with Hodgkin's lymphoma is prognostic of clinical outcome.
41. Lin, E. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238-11246 (2006). (Pubitemid 46009952)
42. Qian, B. et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4, e6562 (2009).
43. This study demonstrated that macrophages have a crucial role in metastatic cell seeding and in the progression of metastatic disease.
44. Zheng, Y. et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114, 3625-3628 (2009).
45. Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity 32, 593-604 (2010).
46. DeNardo, D. G. et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91-102 (2009).
47. This study demonstrated that, in transgenic mice with mammary carcinomas, TAMs develop a pro-tumour and pro-metastatic phenotype in response to CD4+ T cell-derived IL-4. These findings demonstrate that the adaptive immune system plays a substantial part in driving the pro-tumour activity of the innate immune system.
48. Murai, M. et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nature Immunol. 10, 1178-1184 (2009).
49. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004). (Pubitemid 39273735)
50. Torroella-Kouri, M. et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 69, 4800-4809 (2009).
51. Kuang, D. M. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327-1337 (2009).
52. This study demonstrated that CD68+ monocytes in the peritumoural stroma of patients with hepatocellular carcinoma express PDL1, induce T cell anergy, promote tumour progression and are associated with poor survival.
53. Rodriguez, P. C. et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839-5849 (2004). (Pubitemid 39095585)
54. Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225 (2011).
55. Using a transgenic mouse mammary carcinoma system, this study demonstrated that tumour cells and stromal cells produce CCL2, which recruits inflammatory monocytes and macrophages that promote metastasis. Blocking CCL2-CCR2 signalling inhibits the recruitment of inflammatory monocytes, inhibits metastasis and increases survival rates.
56. O'Connell, P. A., Surette, A. P., Liwski, R. S., Svenningsson, P. & Waisman, D. M. S100A10 regulates plasminogen-dependent macrophage invasion. Blood 116, 1136-1146 (2010).
57. Phipps, K., Surette, A., O'Connell, P. & Weaisman, D. Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res. 71, 6676-6683 (2011).
58. Movahedi, K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6Chigh monocytes. Cancer Res. 70, 5728-5739 (2010).
59. This study demonstrated that distinct subpopulations of TAMs can be identified based on their expression of M1-and M2-like markers and that these different subpopulations localize to different regions of solid tumours, where they have distinct functions.
60. Pucci, F. et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114, 901-914 (2009).
61. Ojalvo, L. S., Whittaker, C. A., Condeelis, J. S. & Pollard, J. W. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J. Immunol. 184, 702-712 (2010).
62. Tiemessen, M. M. et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl Acad. Sci. USA 104, 19446-19451 (2007).
63. Song, L. et al. Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 119, 1524-1536 (2009).
64. de Visser, K. E., Korets, L. V. & Coussens, L. M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423 (2005). (Pubitemid 40719125)
65. Wong, S. C. et al. Macrophage polarization to a unique phenotype driven by B cells. Eur. J. Immunol. 40, 2296-2307 (2010).
66. Andreu, P. et al. FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17, 121-134 (2010).
67. Hagemann, T. et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol. 176, 5023-5032 (2006).
68. Summers, C. et al. Neutrophil kinetics in health and disease. Trends Immunol. 31, 318-324 (2010).
69. Donskov, F. & von der Maase, H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J. Clin. Oncol. 24, 1997-2005 (2006). (Pubitemid 46622107)
70. Jensen, H. K. et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709-4717 (2009).
71. Ilie, M. et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 118, 1726-1737 (2012).
72. Li, Y. W. et al. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497-505 (2011).
73. Sparmann, A. & Bar-Sagi, D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458 (2004). (Pubitemid 39469981)
74. Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007). (Pubitemid 350231321)
75. Kowanetz, M. et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl Acad. Sci. USA 107, 21248-21255 (2010).
76. Nozawa, H., Chiu, C. & Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103, 12493-12498 (2006). (Pubitemid 44267286)
77. Houghton, A. M. et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Med. 16, 219-223 (2010).
78. Granot, Z. et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20, 300-314 (2011).
79. Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 16, 183-194 (2009).
80. In this study, neutrophils are shown to undergo a TGFβ-regulated shift between different transitional activation stages.
81. De Santo, C. et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nature Immunol. 11, 1039-1046 (2010).
82. Davey, M. S. et al. Failure to detect production of IL-10 by activated human neutrophils. Nature Immunol. 12, 1017-1018 (2011).
83. Gabrilovich, D. I. et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67, 425-426 (2007).
84. Peranzoni, E. et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238-244 (2010).
85. Greten, T. F., Manns, M. P. & Korangy, F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 11, 802-807 (2011).
86. Dolcetti, L. et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40, 22-35 (2010).
87. Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802 (2008).
88. Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233-4244 (2008).
89. Mandruzzato, S. et al. IL4Rα+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182, 6562-6568 (2009).
90. Haile, L. A., Gamrekelashvili, J., Manns, M. P., Korangy, F. & Greten, T. F. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J. Immunol. 185, 203-210 (2010).
91. Van Ginderachter, J. A. et al. Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 108, 525-535 (2006). (Pubitemid 44061352)
92. Bronte, V. et al. Identification of a CD11b +Gr-1 +CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood 96, 3838-3846 (2000).
93. Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155-1166 (2007). (Pubitemid 46718400)
94. Kusmartsev, S. et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14, 8270-8278 (2008).
95. Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59 (2009).
96. Solito, S. et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118, 2254-2265 (2011).
97. A relationship between human MDSCs and immature promyelocytes is identified in this study. More importantly, the levels of these cells in the blood are shown to be inversely correlated with the response to chemotherapy in patients with breast or colon cancer.
98. Corzo, C. A. et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182, 5693-5701 (2009).
99. Raychaudhuri, B. et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology 13, 591-599 (2011).
100. Rodriguez, P. C. et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69, 1553-1560 (2009).
101. Vuk-Pavlovic, S. et al. Immunosuppressive CD14+ HLA-DRlow/-monocytes in prostate cancer. Prostate 70, 443-455 (2010).
102. Hoechst, B. et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology 135, 234-243 (2008). (Pubitemid 351899008)
103. Filipazzi, P. et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553 (2007). (Pubitemid 47041228)
104. Serafini, P. et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203, 2691-2702 (2006). (Pubitemid 44833345)
105. Youn, J.-I., Collazo, M., Shalova, I., Biswas, S. & Gabrilovich, D. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91, 167-181 (2012).
106. Brandau, S. et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 89, 311-317 (2011).
107. Lu, T. et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121, 4015-4029 (2011).
108. Bronte, V. & Zanovello, P. Regulation of immune responses by l-arginine metabolism. Nature Rev. Immunol. 5, 641-654 (2005). (Pubitemid 41113195)
109. Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nature Med. 13, 828-835 (2007). (Pubitemid 47038194)
110. Molon, B. et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208, 1949-1962 (2011).
111. References 99, 101 and 102 illustrate the complex negative influence on T cells of peroxynitrite, which is produced in the tumour environment or in tumour-draining lymph nodes by either myeloid or tumour cells.
112. Raes, G. et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J. Immunol. 174, 6561 (2005).
113. Lechner, M. G., Liebertz, D. J. & Epstein, A. L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 185, 2273-2284 (2010).
114. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 9, 162-174 (2009).
115. Li, Q., Pan, P. Y., Gu, P., Xu, D. & Chen, S. H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res. 64, 1130-1139 (2004). (Pubitemid 38176920)
116. Narita, Y., Wakita, D., Ohkur, T., Chamoto, K. & Nishimura, T. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed. Res. 30, 7-15 (2009).
117. Kusmartsev, S. & Gabrilovich, D. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174, 4880-4891 (2005).
118. Corzo, C. A. et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207, 2439-2453 (2010).
119. This study demonstrated that MDSCs in the tumour microenvironment rapidly differentiate into TAMs and that this effect is mediated by hypoxia.
120. Doedens, A. L. et al. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465-7475 (2010).
121. Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P. & Ostrand-Rosenberg, S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70, 68-77 (2010).
122. Schmielau, J. & Finn, O. J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61, 4756-4760 (2001). (Pubitemid 32691887)
123. Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168, 689-695 (2002). (Pubitemid 34049569)
124. Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D. & Ostrand-Rosenberg, S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183, 937-944 (2009).
125. Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C. & Kuchroo, V. K. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 32, 345-349 (2011).
126. Li, H., Han, Y., Guo, Q., Zhang, M. & Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J. Immunol. 182, 240-249 (2009).
127. Hoechst, B. et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50, 799-807 (2009).
128. Elkabets, M. et al. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40, 3347-3357 (2010).
129. Pan, P. Y. et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 70, 99-108 (2010).
130. Huang, B. et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131 (2006). (Pubitemid 43165981)
131. Serafini, P., Mgebroff, S., Noonan, K. & Borrello, I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68, 5439-5449 (2008).
132. Hoechst, B., Gamrekelashvili, J., Manns, M. P., Greten, T. F. & Korangy, F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 117, 6532-6541 (2011).
133. Watanabe, S. et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J. Immunol. 181, 3291-3300 (2008).
134. Sinha, P. et al. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 117, 5381-5390 (2011).
135. Gallina, G. et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116, 2777-2790 (2006). (Pubitemid 44511641)
136. Nagaraj, S. et al. Antigen-specific CD4+ T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 72, 928-938 (2012).
137. Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M. & Ostrand-Rosenberg, S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179, 977-983 (2007).
138. Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499-4506 (2009).
139. Bunt, S. K., Clements, V. K., Hanson, E. M., Sinha, P. & Ostrand-Rosenberg, S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leukoc. Biol. 85, 996-1004 (2009).
140. Hu, C. E., Gan, J., Zhang, R. D., Cheng, Y. R. & Huang, G. J. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand. J. Gastroenterol. 46, 156-164 (2011).
141. Marigo, I. et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32, 790-802 (2010).
142. This study shows that the transcription factor C/EBPβ, which is essential for emergency granulopoiesis during inflammatory conditions, regulates the immunosuppressive activity of myeloid cells that are conditioned by growing tumours and provides the basis for molecular targeting of common tolerogenic pathways in myeloid cells.
143. Sinha, P. et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181, 4666-4675 (2008).
144. Bunt, S. K., Sinha, P., Clements, V. K., Leips, J. & Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176, 284-290 (2006). (Pubitemid 43023273)
145. Yang, L. et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23-35 (2008). (Pubitemid 350309741)
146. Huang, B. et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 252, 86-92 (2007). (Pubitemid 46734559)
147. Greifenberg, V., Ribechini, E., Rossner, S. & Lutz, M. B. Myeloid-derived suppressor cell activation by combined LPS and IFN-γ treatment impairs DC development. Eur. J. Immunol. 39, 2865-2876 (2009).
148. Sinha, P., Clements, V. K., Fulton, A. M. & Ostrand-Rosenberg, S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67, 4507-4513 (2007). (Pubitemid 46815102)
149. Zhang, H. G. & Grizzle, W. E. Exosomes and cancer: a newly described pathway of immune suppression. Clin. Cancer Res. 17, 959-964 (2011).
150. Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med. 10, 48-54 (2004). (Pubitemid 38524698)
151. Cheng, F. et al. A critical role for Stat3 signaling in immune tolerance. Immunity 19, 425-436 (2003). (Pubitemid 37153418)
152. Nefedova, Y. et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172, 464-474 (2004). (Pubitemid 38020502)
153. Nefedova, Y. et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65, 9525-9535 (2005). (Pubitemid 41508023)
154. Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V. & Kiessling, R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-SIGN. Cancer Res. 70, 4335-4345 (2010).
155. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Rev. Cancer 9, 798-809 (2009).
156. Foell, D., Wittkowski, H., Vogl, T. & Roth, J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 81, 28-37 (2007). (Pubitemid 46021248)
157. Cheng, P. et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
158. Farren, M. R., Carlson, L. M. & Lee, K. P. Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase CβII expression. Immunol. Res. 46, 165-176 (2010).
159. Zhang, H. et al. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116, 2462-2471 (2010).
160. Sander, L. E. et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 207, 1453-1464 (2010).
161. Sinha, P., Clements, V. & Ostrand-Rosenberg, S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174, 636-645 (2005). (Pubitemid 40094255)
162. Sinha, P., Clements, V. K. & Ostrand-Rosenberg, S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65, 11743-11751 (2005). (Pubitemid 41821736)
163. Bronte, V. et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170, 270-278 (2003). (Pubitemid 36026149)
164. Terabe, M. et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198, 1741-1752 (2003). (Pubitemid 37494166)
165. Munera, V. et al. Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann. Surg. 251, 120-126 (2010).
166. Ishii, M. et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 114, 3244-3254 (2009).
167. This study demonstrates that M2 macrophage polarization is partially regulated epigenetically by chromatin or histone remodelling through an IL-4-and STAT6-dependent mechanism.
168. Satoh, T. et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nature Immunol. 11, 936-944 (2010).
169. Martino, A. et al. Mycobacterium bovis bacillus Calmette-Guérin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production. J. Immunol. 184, 2038-2047 (2010).
170. Liu, Y. et al. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am. J. Pathol. 176, 2490-2499 (2010).
171. Zhang, Y. et al. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J. Immunol. 182, 3801-3808 (2009).
172. Donkor, M. K. et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int. Immunopharmacol. 9, 937-948 (2009).
173. Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J. & Kusmartsev, S. Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J. Leukoc. Biol. 88, 839-848 (2010).
174. Rodriguez, P. C. et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202, 931-939 (2005). (Pubitemid 41396893)
175. Clark, C. E. et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67, 9518-9527 (2007). (Pubitemid 47535942)
176. Lesina, M. et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456-469 (2011).
177. Fukuda, A. et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19, 441-455 (2011).
178. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
179. Pufnock, J. S. & Rothstein, J. L. Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J. Immunol. 182, 5498-5506 (2009).
180. Borrello, M. G. et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl Acad. Sci. USA 102, 14825-14830 (2005). (Pubitemid 41457140)
181. Melani, C., Chiodoni, C., Forni, G. & Colombo, M. P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145 (2003). (Pubitemid 37122391)
182. Stairs, D. B. et al. Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell 19, 470-483 (2011).
183. In the model of autochthonous cancer, soluble factors released by tumour cells recruited and promoted the proliferation of immature myeloid cells, which possess immunosuppressive properties and promote desmoplasia by activating fibroblasts.
184. Highfill, S. L. et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116, 5738-5747 (2010).
185. De Santo, C. et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl Acad. Sci. USA 102, 4185-4190 (2005). (Pubitemid 40388577)
186. Nagaraj, S. et al. Anti-inflammatory triterpenoid blocks immune suppressive function of myeloid-derived suppressor cells and improves immune response in cancer. Clin. Cancer Res. 16, 1812-1823 (2010).
187. Ko, J. S. et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70, 3526-3536 (2010).
188. Ko, J. S. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148-2157 (2009).
189. Ozao-Choy, J. et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69, 2514-2522 (2009).
190. van Cruijsen, H. et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 14, 5884-5892 (2008).
191. Xin, H. et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69, 2506-2513 (2009).
192. Veltman, J. D. et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 10, 464 (2010).
193. Pan, P. Y. et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111, 219-228 (2008).
194. DeNardo, D. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011).
195. Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z. & Colombo, M. P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67, 11438-11446 (2007). (Pubitemid 350248572)
196. Veltman, J. D. et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br. J. Cancer 103, 629-641 (2010).
197. Fernandez, A. et al. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J. Immunol. 186, 264-274 (2011).
198. Priceman, S. J. et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115, 1461-1471 (2010).
199. Fricke, I. et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13, 4840-4848 (2007). (Pubitemid 47298146)
200. Kusmartsev, S. et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 181, 346-353 (2008).
201. Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. & Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1 +CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721 (2005). (Pubitemid 41339014)
202. Vincent, J. et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061 (2010).
203. Kodumudi, K. N. et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16, 4583-4594 (2010).
204. Mirza, N. et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299-9307 (2006). (Pubitemid 44521152)
205. Kusmartsev, S. et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63, 4441-4449 (2003). (Pubitemid 36951016)
206. Lathers, D., Clark, J., Achille, N. & Young, M. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol. Immunother. 53, 422-430 (2004). (Pubitemid 38657255)
207. Watkins, S. K., Egilmez, N. K., Suttles, J. & Stout, R. D. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol. 178, 1357-1362 (2007). (Pubitemid 46154605)
208. Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G. & Colombo, M. P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437-3446 (2005). (Pubitemid 40524630)
209. Kerkar, S. P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746-4757 (2011).
210. Chmielewski, M., Kopecky, C., Hombach, A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that shut down tumor antigen expression. Cancer Res. 71, 5697-5706 (2011).
211. References 196 and 197 show that it is possible to reprogramme the tumour environment through the adoptive transfer of T cells that recognize a tumour antigen and that are engineered to release IL-12.
212. Weiss, J. M. et al. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med. 207, 2455-2467 (2010).
213. Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
214. Rolny, C. et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31-44 (2011).
215. Hagemann, T. et al. "Re-educating" tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 205, 1261-1268 (2008). (Pubitemid 351831483)